Venous thromboembolism (VTE) is a common disease (~ 700 per 100 000) that is
associated with significant risk of recurrence, chronic complications, and substantial
mortality, with reported death rates of up to 40% at 10 years. The development of novel
anticoagulants has revolutionized the treatment of acute VTE, while strategies for prevention
and treatment of chronic complications still seek for such a landmark change. Impaired
thrombus resolution is the common denominator behind VTE complications, which are …